328547-12-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Methyl 2-bromo-5-fluoro-3-nitrobenzoate is utilized as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and reactivity contribute to the development of new and effective compounds for these industries.
Used in Organic Synthesis:
methyl 2-bromo-5-fluoro-3-nitrobenzoate serves as a building block in organic synthesis, particularly in the preparation of various aromatic compounds. Its versatility in chemical reactions allows for the creation of a wide range of specialty chemicals.
Safety Considerations:
It is important to handle methyl 2-bromo-5-fluoro-3-nitrobenzoate with care and follow proper safety protocols due to its potential hazards. This ensures the safety of individuals working with the compound and minimizes any risks associated with its use.

Upstream product

• 2475-81-2 methyl 4-fluoroanthranilate 
• 1055331-73-1 2-bromo-5-fluoro-3-nitrobenzoic acid 
• 394-28-5 2-Bromo-5-fluorobenzoic acid 
• 67-56-1 methanol 
• 328547-11-1 2-amino-5-fluoro-3-nitrobenzoic acid methyl ester 
• 443-69-6 5-fluoro-1H-indole-2,3-dione 
• 954571-39-2 5-fluoro-7-nitroindoline-2,3-dione 

Downstream Products

• 884497-46-5 methyl 3-amino-5-fluorobenzoate 
• 1342063-52-8 methyl 3-amino-2-bromo-5-fluorobenzoate 
• 328543-84-6 4-Fluoro-1-(4-hydroxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one 
• 1055331-73-1 2-bromo-5-fluoro-3-nitrobenzoic acid 

Relevant academic research and scientific papers

Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors

The nuclear protein poly(ADP-ribose) polymerases-1/2 (PARP-1/2) are involved in DNA repair damaged by endogenous or exogenous process. And PARP-1/2 inhibitors have been proved to be clinically efficacious for DNA repair deficient tumors in the past decade

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R1a, R2a, R1b, R2b, R1c, R2c, p and q are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, p and q are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS

This invention is directed to, for example, compounds of formula (I): wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Tricyclic inhibitors of poly(ADP-ribose) polymerases

Compounds of the formula shown below are poly(ADP-ribosyl)transferase inhibitors: Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.